



PTO/ISB/08a/5 (07-05)  
 Approved for use through 07/31/2008. OMB 0851-0031  
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO			<b>Complete If Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			Application Number	10/510,361	
			Filing Date	June 20, 2005	
			First Named Inventor	Hubert Eng	
			Art Unit	1614	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	AREX-P01-015

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†*
	BC	WO 98/57661	12-23-1998	Altarex Corp.		
	BD	WO 02/076384 A2	10-03-2002	Altarex Corp.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinda Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document, by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			†*
	CH	AltaRex Corp. "AltaRex Corp. (AXO) Reports Favorable OvaRex <sup>TM</sup> Phase II Trial Results", Biospace, 1/3/2001, pp 1.			
	CI	SCHULTES, et al., "Induction of tumor- and CA125-specific T cell responses in patients (pts) with epithelial ovarian cancer (EOC) treated with OvaRex <sup>TM</sup> ", Proceedings of the American Association for Cancer Research, Volume 43, March 2002, pp. 144 (Abstract only).			
	CJ	NOUJAIM, A. et al., Induction of CA125-Specific B and T Cell Responses in Patients Injected with Mab-B43.13 – Evidence for Antibody-Mediated Antigen-Processing and Presentation of CA125 in Vivo, Cancer Biotherapy & Radiopharmaceuticals, Volume 16, Number 3, 2001, pp. 187-203.			
	CK	SCHULTES, B. et al., "Antibody-antigen immune complexes allow for efficient MHC class I and II-restricted antigen presentation and maturation of dendritic cells: a novel strategy for cancer immunotherapy", Proceedings of the 92 <sup>nd</sup> Annual Meeting of The American Association for Cancer Research, New Orleans, LA, March 24-28, 2001, Proceedings of the Annual Meeting of The American Association for Cancer Research, Philadelphia, PA: ACCR, US, Vol. 42, March 24, 2001, pp. 276 (Abstract only)			
	CL	EHLLEN, T., et al., "Induction of tumor protective immunity utilizing the CA125 specific monoclonal, OvaRex, Mab-B43.13, in a cohort of patients with advanced recurrent ovarian cancer", Thirty-second Annual Meeting of the Society of Gynecologic Oncologists, Nashville, Tennessee, March 3-7, 2001 (Abstract only)			
	CM	BRUKNER, I. et al., OvaRex AltaRex, IDrugs: The Investigational Drugs Journal, vol. 4, no. 4, April 2001, pp. 457-462.			
	CN	MOINGEON, P., "Cancer vaccines", Vaccine, 19 (2001) pp. 1305-1326.			
	CO	SCHULTES, B. et al., "Immunotherapy of Human Ovarian Carcinoma with OVAREX <sup>TM</sup> Mab-B43.13 in a Human-PBL-SCID/BG Mouse Model", Hybridoma, Vol. 18, No. 1, 1999, pp. 47-55.			
	CP	MADIYALAKAN, R. et al., "Antidiotype Induction Therapy: Evidence for the Induction of Immune Response through the Idiotype Network in Patients with Ovarian Cancer after			

Examiner Signature	/Brad Duffy/	Date Considered	05/23/2008
--------------------	--------------	-----------------	------------

3150022

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BD/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/510,361
				Filing Date	June 20, 2005
				First Named Inventor	Hubert Eng
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	AREX-P01-015

		Administration of Anti-CA125 Murine Monoclonal Antibody B43.13", Hybridoma, Vol. 14, No. 2, 1995, pp. 199-203.	
	CQ	OLTROGGE, J.B. et al., "Generation of human monoclonal anti-idiotypic antibodies with specificity to the murine monoclonal anti-CA 125 antibody B43.13", The International Journal of Biological Markers, 1996 Oct-Dec, Vol. 11, No. 4, October 1996, pp. 211-215.	
	CR	COCCIA, M. et al., "High Titer, Prostate Specific Antigen-Specific Human IgG Production by hu-PBL-SCID Mice Immunized with Antigen-Mouse IgG2a Complex-Pulsed Autologous Dendritic Cells", Journal of Immunology, Vol. 161, No. 10, November 15, 1998, pp. 5772-5780.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BD/

Examiner Signature	/Brad Duffy/	Date Considered	05/23/2008
--------------------	--------------	-----------------	------------